Catalyst Pharmaceuticals

AGAMREE is a prescription medicine for Duchenne muscular dystrophy (DMD), indicated for patients aged 2 years and older. Its active ingredient, vamorolone, is a corticosteroid supplied as an oral suspension at a concentration of 40 mg/mL. The brand’s healthcare professional website provides information to support clinicians in evaluating and prescribing treatment, including summaries of clinical trial efficacy and safety, study design, long-term data, dosing, administration, and prescribing instructions.

The site also directs healthcare professionals to patient access and support resources, including Catalyst Pathways, which offers personalized assistance with access and affordability. Visitors can request a representative, sign up for updates, and access medical information, while patients and caregivers can find an enrollment form and links to a patient-focused site.

AGAMREE’s prescribing information outlines important precautions associated with corticosteroid treatment, including risks affecting endocrine function, infection, mood, bones, and growth. The website encourages healthcare professionals to consult the full prescribing information and provides contact details for reporting suspected adverse reactions.